UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average b	urden
hours per response	. 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

e Responses)														
Name and Address of Reporting Person* Floyd Robert Michael				2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
CESSA PH		CALS,	3. Date of Earliest Transaction (Month/Day/Year) 07/08/2021					X Officer (give title below) Other (specify below) Chief Operating Officer						
FR MD 210	(Street)	4	4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person				
	(State)	(Zip)	Table I - Non-Derivative Securities Acc				es Acquired	uired, Disposed of, or Beneficially Owned						
curity	I	Oate	Execution any	Dat	rear)	le tr. 8)	(A) c (Inst	or Disposed of 3, 4 and 5) (A) or	of (D) Ow Trai	ired (D) Owned Following Report Transaction(s) (Instr. 3 and 4)			Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
eport on a sep	parate line for each	Table II -	Derivative	Sec	curities A	cquii	Persons v contained form disp	in this for lays a curr d of, or Ben	m are not ently valid	required I OMB co	to respon	d unless the		474 (9-02)
2. Conversion or Exercise Price of Derivative Security	Exercise (Month/Day/Year) ice of erivative	3A. Deemed Execution Date, if	4. if Transaction Code ar) (Instr. 8)		5. Number of Derivative Securities		6. Date Exercisable and Expiration Date (Month/Day/Year) S		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			Derivative Securities Beneficially Owned Following Reported	Ownershi Form of Derivative Security: Direct (D or Indirec	(Instr. 4)
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
\$ 0	07/08/2021		A		8,572		<u>(1)</u>	(1)	Commor Stock	8,572	\$ 0	8,572	D	
\$ 0	07/08/2021		A		12,858		(2)	<u>(2)</u>	Commor Stock	12,858	\$ 0	12,858	D	
\$ 0	07/08/2021		A		1,907		<u>(3)</u>	(3)	Commor Stock	10,034	\$ 0	10,034	D	
	2. Conversion or Exercise Price of Derivative Security \$ 0	Address of Reporting Person bert Michael (First) CESSA PHARMACEUTIC O COCA COLA DRIVE, Set (Street) ER, MD 21076 (State) Ceurity 2. Conversion or Exercise Price of Derivative Security \$0 07/08/2021 \$0 07/08/2021	Address of Reporting Person— Deert Michael (First) (Middle) (CESSA PHARMACEUTICALS, 0 COCA COLA DRIVE, SUITE 106 (Street) ER, MD 21076 (State) 2. Transaction Date (Month/Day/Year) Report on a separate line for each class of securities 1 any (Month/Day/Year) Table II - (Month/Day/Year) 3. Transaction Date (Month/Day/Year) (Month/Day/Year) Security Security 3. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Transaction Date (Month/Day/Year) (Month/Day/Year)	Address of Reporting Person Processa (First) (Middle) (CESSA PHARMACEUTICALS, 0 COCA COLA DRIVE, SUITE 106 (Street) 4. If Amen ER, MD 21076 (State) (Zip) (Curity 2. Transaction Date (Month/Day/Year) (Month/Day/Year) Execution or Exercise Price of Derivative Security 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Transaction Date Execution Date (Month/Day/Year) (A. If Amen Table II - Derivative (a.g., puts, any (Month/Day/Year)) (Month/Day/Year) (A. Transaction Date (Month/Day/Year) (A. Transaction Date (Month/Day/Year) (A. Transaction Date, if any (Month/Da	Address of Reporting Person bent Michael (First) (Middle) (Middle	Address of Reporting Person*- pert Michael (First) (Middle) (CESSA PHARMACEUTICALS, 0 COCA COLA DRIVE, SUITE 106 (Street) 4. If Amendment, Date of Earliest Trans 07/08/2021 (Street) 4. If Amendment, Date of Earliest Trans 07/08/2021 (Street) 4. If Amendment, Date of Earliest Trans 07/08/2021 (Street) 4. If Amendment, Date of Earliest Trans 07/08/2021 (Street) 4. If Amendment, Date of Earliest Trans 07/08/2021 (Street) 4. If Amendment, Date of Earliest Trans 07/08/2021 (Instruction Date of Earliest Trans 07/08/2021 (A. Deemed Execution Date, if Oxide any (Month/Day/Year)) (Instr. 3) 5. Numb Execution Date, if Oxide or Disponsor Exercise (Month/Day/Year) (Instr. 8) Acquire or Disponsor Oxide of (D) (Instr. 3) (Instr. 3	Address of Reporting Person bert Michael (First) (Middle) (CESSA PHARMACEUTICALS, 0 COCA COLA DRIVE, SUITE 106 (Street) (State) (Zip) (All Famendment, Date Origin 2R, MD 21076 (State) (Zip) (All Famendment, Date Origin 2R, MD 21076 (State) (Zip) (All Famendment, Date Origin 2R, MD 21076 (State) (Zip) (All Famendment, Date Origin 2R, MD 21076 (Month/Day/Year) (Month/Day/Year) (All Famendment, Date Origin 2R, MD 21076 (State) (Zip) (All Famendment, Date Origin 2R, MD 21076 (Month/Day/Year) (All Famendment, Date Origin 2R, MD 21076 (Month/Day/Year) (All Famendment, Date Origin 2R, MD 21076 (All Famendment, Date Origin 2R, Deemed 2R, D	2. Issuer Name and Ticker or Trading Sy Processa Pharmaceuticals, Inc. [PC (First) (Middle) (CESSA PHARMACEUTICALS, 0 COCA COLA DRIVE, SUITE 106 (Street) 3. Date of Earliest Transaction (Month/Day/708/2021 4. If Amendment, Date Original Filed(Month/Day/Year) 3. Transaction Date (Month/Day/Year) 4. Securition Date, if (Month/Day/Year) 4. Securition Date, if (Month/Day/Year) 5. Number of Derivative Securities Securities Securities Securities Acquired, Disposed (Month/Day/Year) 7. Table II - Derivative Securities Acquired, Disposed (Month/Day/Year) 8. A Deemed Execution Date, if (Inst. 8) 8. Transaction Date (Month/Day/Year) 9. Table II - Derivative Securities Acquired, Disposed (Month/Day/Year) 1. Tansaction Date (Month/Day/Year) 1. Transaction Date (Month/Day/Year) 1. Transaction Date (Month/Day/Year) 2. Transaction Date (Post of Derivative Securities Acquired, Disposed (Month/Day/Year) 1. Transaction Date (Month/Day/Year) 2. Transaction Date (Post of Derivative Securities Acquired, Disposed (Month/Day/Year) 2. Transaction Date (Post of Derivative Securities Acquired, Disposed (Month/Day/Year) 3. Transaction Date (Post of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 4. Date Exercisable (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 4. Date Exercisable (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA] 3. Date of Earliest Transaction (Month/Day/Year) 6. OCOCA COLA DRIVE, SUITE 106 (Street) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (Instr. 3, 4 and 5) 4. Securities Acquired (A) or Disposed (Instr. 3, 4 and 5) Table II - Derivative Securities S	Address of Reporting Person Detrivative Securities Acquired (Instr. 3) Amount (Instr. 3) Amount (Instr. 3) Amount (Instr. 3) Code of Code (Month/Day/Year) Code of Code (Month/D	Address of Reporting Person	Address of Reporting Person	2. Issuer Name and Ticker or Trading Symbol Processas Pharmaceuticals, Inc. [PCSA] 5. Relationship of Reporting Person() 6. CESSA PHARMACEUTICALS, 0 COCA COLA DRIVE, SUITE 106 6. Individual or Joint/Group FilingChesk S. Pharmaceuticals (Month/Day/Year) 6. Individual or Joint/Group FilingChesk S. Transaction (Instr. 3) and 4) 6. Individual or Joint/Group FilingChesk S. Transaction (Instr. 3) and 4) 6. Individual or Joint/Group FilingChesk S. Transaction (Instr. 3) and 4) 6. Individual or Joint/Group FilingChesk S. Transaction (Instr. 3) and 4) 6. Individual or Joint/Group FilingChesk S. Transaction (Instr. 3) and 4) 6. Individual or Joint/Group FilingChesk S. Transaction (Instr. 3) and 4) 6. Individual or Joint/Group FilingChesk S. Transaction (Instr. 3) and 4) 6. Individual or Joint/Group FilingChesk S. Transaction (Instr. 3) and 4) 6. Individual or Joint/Group FilingChesk S. Transaction (Instr. 3) and 4) 6. Individual or Joint/Group FilingChesk S. Transaction (Instr. 3) and 4) 6. Individual or Joint/Group FilingChesk S. Transaction (Instr. 3) and 4) 6. Individual or Joint/Group FilingChesk S. Transaction (Instr. 3) and 4) 6. Individual or Joint/Group FilingChesk S. Transaction (Instr. 3) and 4) 7. Amount (Instr. 3) and 5 (Instr. 3) and 4 (Instr. 4) (Instr. 4	Address of Reporting Person 2 Assuer Name and Ticker or Trailing Symbol Processa Pharmaceuticals, Inc. PCSA December (Check all applicable) December (Check all appl

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Floyd Robert Michael C/O PROCESSA PHARMACEUTICALS, INC. 7380 COCA COLA DRIVE, SUITE 106 HANOVER, MD 21076			Chief Operating Officer					

Signatures

/s/ Michael Floyd by Michael B. Kirwan, as Attorney-in-Fact	07/09/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The restricted stock units vest in two equal installments beginning July 1, 2022.
- (2) The Restricted Stock Units vest upon achievement of certain performance goals.
- (3) Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.